



Problems and Prospects of Research in the Americas and Eurasia

III International Academic Congress

(Buenos Aires, Argentina, 3-5 December 2014)

PAPERS AND COMMENTARIES

VOLUME I

"Buenos Aires University Press"
Buenos Aires
2015

Proceedings of the III International Academic Congress “Problems and Prospects of Research in the Americas and Eurasia” (Buenos Aires, Argentina, 3-5 December 2014). Volume I. “Buenos Aires University Press”, Buenos Aires, 2015. - 526 p.

Proceedings of the Conference are located in the Databases Scopus.
Source Normalized Impact per Paper (SNIP): 2.846
SCImago Journal Rank (SJR): 2.928

Editor-in-Chief: *Prof. Louis de Silva, D. I. T. (Argentina)*
Publication Director: *Prof. Christina Menem, D. Litt. (Argentina)*
Technical Editors: *Roberto Santos, Luisa Pereira (Argentina)*

ORGANIZATION BOARD OF THE CONGRESS:

Chairman: *Prof. Louis de Silva, D. I. T. (Argentina)*
Secretaries: *Prof. Christina Menem, D. Litt. (Argentina)*
 Prof. Anna Maria Galba, D. M. (Spain)

Members of the Board:

Prof. Antonio Gonzalez, D. S. Sc. (Argentina)
Prof. Eduardo Santero, D. M. Sc. (Argentina)
Prof. Jose Alvarez, D. S. Sc. (Spain)
Prof. Daniel Smith, D.F. (Canada)
Prof. Carlos Aguilarite, D. M. Sc. (Argentina)
Prof. Sienna Paige, D. B. A. (USA)
Prof. Pedro Ferreira, D. I. T. (Argentina)
Prof. Harry Read, D. B. A. (UK)
Prof. Eduardo Solanos, D. C. S. (Argentina)
Prof. Jean Lavanan, D. I. T. (France)
Prof. Lucélia Fernandez, D. E. Sc. (Argentina)
Prof. Philippe Moretti, D. Env. (France)
Prof. Jean-Marie Attalie, D. P. E. (France)
Prof. Robert Barclay, D. C. S. (UK)
Prof. Dominic Stiles, D. P. E. (Canada)
Prof. Paulo Rubio, D. M. Sc. (Italy)
Prof. Jean-Claude Brim, D. E. Sc. (France)
Prof. Maria Gomes, Ed.D. (Argentina)
Prof. Leslie Bragg, Psy. D. (Canada)
Prof. Paul Bryant, Psy. D. (UK)
Prof. Linda Graves, Psy. D. (USA)
Prof. Ronald Hall, D. G. S. (USA)

*Prazdnova E.V., Chistyakov V.A., Mazanko M.S.,
Chmyhalo V.K., Churilov M.N.,
Academy of biology and biotechnology,
Southern federal university*

Determination of the specificity of ROS generation by the action of platinum-based drugs in SOS-lux test

Antineoplastic drugs based on platinum compounds are widespread in anticancer therapy. High efficacy of these drugs is due to their ability to selectively affect rapidly reproducing tumor cells by damaging DNA and launching mechanisms of apoptosis [1,2].

Use of cisplatin is greatly limited by two factors. Firstly, there is a wide range of side effects. Secondly, cisplatin has a strong genotoxic and mutagenic effect, as shown in several studies [3,4]. DNA damage induced by cisplatin can lead to secondary tumors years after chemotherapy [5]. Furthermore, the drug may cause mutations resulting in resistance to both cisplatin and other drugs [6].

Latest data show that the cytotoxic effects of these compounds may also be mediated by the generation of reactive oxygen species (ROS) and the occurrence of oxidative stress [7-11]. Apparently, ROS generation may be associated with side effects of these drugs: cisplatin nephrotoxicity, cisplatin and oxaliplatin ototoxicity and occurrence of secondary tumors [11-13].

The aim of this study was to investigate the genotoxicity of platinum-based drugs mediated by oxidative stress in a simple model system. A set of bacterial biosensors responding to oxidative stress and DNA damage was used. This technique was successfully used previously in study of prooxidant and antioxidant properties of a wide range of compounds and drugs [14], as well as physical factors [15]. The theoretical possibility of determining the genotoxicity of platinum drugs in the same test was shown by our colleagues from the State Research Institute of Genetics [16].

In this study, we used biosensors reacting to various ROS to figure out if there are specific features in action of two drugs.

We used *E.coli* strains MG1655 (pKatG-lux), MG1655 (pSoxS-lux), and MG1655 (pCold-lux), containing the plasmid carrying the operon luxCDABE under control of promoters

of kat-operon, sox-operon and colD genes (cda promoter). Biosensor with the promoter PkatG registers formation of hydrogen peroxide in the cell; soxS promoter reacts to the increased superoxide-anion-radical level; biosensor with the promoter Pcda registers DNA damage (Zavilgelsky et al). Strains were provided by I. V. Manukhov (State Scientific Center Genetika, Moscow).

Cultures of strains were grown on complete medium Luria-Bertani (LB), with addition of ampicillin (100 µg / ml) for 18-20 hours at 36° C; then culture were diluted by fresh medium until it reached 0,1 McFarland units, and cultured for 2 hours. Aliquots of this culture by 90 µl were transferred to the cells of a microplate (diameter 7 mm), adding 10 µl of preparation solution.

Measurements were carried out every 10 min for 120 min. For evaluation of the influence of the studied factors on Sox-operon expression, the induction factor (I_s) was calculated according to the formula:

$$I_s = L_e / L_k - 1 \quad (1),$$

Where L_k and L_e are luminescence intensities of control and experimental samples, respectively.

A statistically significant excess of L_e over L_k estimated with the t -criterion was considered as a sign of significant influence on the induction effect.

Mean square deviation of SOS-response induction factors were calculated by the formula:

$$s_I = \bar{I} \times \sqrt{\left(\frac{s_{L_e}}{L_e}\right)^2 + \left(\frac{s_{L_k}}{L_k}\right)^2} \quad (2),$$

where e and k are for experimental and control samples, respectively.

Calculation of confidence intervals was made for $p=0,05$.

Study of cisplatin activity in bacterial biosensors.

In biosensor assay high genotoxic activity of cisplatin (fig.1A), and slight induction of superoxide anion radical (fig.1B) was shown, whereas no peroxide generation was observed (maximum induction factor was 0,59, which is statistically insignificant (data not shown)).




Figure 1. A: Inducton of *E.coli* MG1655 (ColD-lux) strain with cisplatinum. Active concentrations are within the range 0,005-50 mg/ml. Maximum induction factor is 95,9. B: Inducton of *E.coli* MG1655 (SoxS-lux) strain with cisplatinum. Active concentrations 0,0005 - 5 mg/ml. Maximum induction factor is 1,04.

Study of oxaliplatin activity in bacterial biosensors.

Genotoxicity of oxaliplatin in biosensor assay was similar to that of cisplatin (Fig 2A). In test with MG1655(KatG-lux) strain, which reacts to peroxide and hydroperoxides, bacterial activity was significantly higher than that of cisplatin.




Figure 2. A: Inducton of *E.coli* MG1655 (ColD-lux) strain with oxaliplatin. Active concentrations - 0,0005-5 mg/ml. Maximum induction factor is 54,85. B: Induction of *E.coli* MG

1655 (KatG-lux) strain with oxaliplatin. Active concentrations 0,00001 – 1 mg/ml. Maximum induction factor - 31,9.

No Lux-operon expression of *E.coli* MG1655(SoxS-lux) under the influence of the drug was observed (data not shown).

In addition to direct interaction with DNA, mutagenic and cytotoxic properties of cisplatin can be performed through induction of oxidative stress and ROS generation [7,8]. This point of view is supported by the fact that certain antioxidants are able to reduce the mutagenic potential of cisplatin[17]. Oxidative stress and the inhibition of antioxidant defense mechanisms is also known to be the main mechanism of cisplatin-induced nephrotoxicity *in vitro* and *in vivo* [1,18-19].

Oxaliplatin is often used as an alternative option to cisplatin. Being transformed *in vivo*, oxaliplatin forms hydrated derivatives, which interact with DNA and interfere with its synthesis. The drug is structurally similar to cisplatin, but contains a non-leaving carrier ligand (DACH) and a hydrolysable oxalate ligand. This modification enhances the anti-tumor activity but alters the side-effect profile of the drug [20].

It is known that oxaliplatin increases ROS production in a dose-dependent manner, and H₂O₂ generated by oxaliplatin can increase the alteration of DNA structure. Moreover, platinum-induced oxidative stress involves oxidation of cellular components and depletion of intracellular antioxidants [8].

It was suggested that one of the causes of peripheral neuropathy in oxaliplatin treatment is precisely the generation of ROS [21]. As in case of cisplatin, there is evidence [13], that natural antioxidants - silibinin and α -tocopherol reduce neurotoxicity of the drug without affecting its antineoplastic activity.

Recent data also indicate the role of ROS in the development of resistance of tumors to treatment with oxaliplatin[22], and it was shown recently that antioxidants may reduce the development of resistance to chemotherapy [13].

According to our experiments, the spectrum and intensity of ROS generation in these two drugs differ. Consequently, side effects can also develop via different mechanisms.

As can be seen in the data, both drugs show a significant genotoxicity in rapid diagnostic tests with bacterial biosensors. Therefore, this test allows to register the main type of activity of the compounds of platinum - DNA damage.

However, in tests with biosensors reacting to oxidative stress, the specificity of action is observed: cisplatin did not cause any significant induction in biosensor registering hydroperoxides (Figure 3), or biosensor that responds to superoxide (Figure 2). Oxaliplatin, on the other hand, caused induction of the catalase operon (Figure 5), but not of superoxide

dismutase genes, which leads to the conclusion about the significant role of the intracellular generation of hydrogen peroxide and its derivatives in the implementation of the genotoxic effect of this drug. With regard to cisplatin apparently role of ROS in the implementation of its effect is not significant.

The distinctions in spectrum of ROS generated in the cell after treatment of cisplatin and oxaliplatin allow us to conclude that the search strategies for additional medicines to eliminate side effects of such drugs should also be different. Since the effects of oxaliplatin are significantly associated with oxidative mechanisms, attention should be paid to the existing antioxidants, particularly mitochondria-targeted.

It should be also noted that the genotoxicity, demonstrated on bacterial models, makes us wonder about the possible mutagenicity of this drug for pathogenic microorganisms, which could acquire resistance to antimicrobial agents under the influence of the drug, making it difficult for traditional treatment. Antioxidants, in addition to reducing the side effects, could reduce the risk of such complications. Study of spectrum of mutations associated with oxidative stress in microorganisms under the treatment with platinum-based drugs, will be the goal of our further research.

References

1. Roland, Peter S., and John A. Rutka, eds. Ototoxicity. PMPH-USA, 2004.
2. Silva, Maria J., et al. "Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells." *Environmental and molecular mutagenesis* 46.2 (2005): 104-115.
3. Burnouf, Dominique, M. Duane, and R. P. Fuchs. "Spectrum of cisplatin-induced mutations in *Escherichia coli*." *Proceedings of the National Academy of Sciences* 84.11 (1987): 3758-3762.
4. Brozovic, G., et al. "Evaluation of DNA damage in vivo induced by combined application of cisplatin and sevoflurane." *European journal of anaesthesiology* 25.08 (2008): 642-647.
5. Brozovic, Gordana, et al. "The in vivo genotoxicity of cisplatin, isoflurane and halothane evaluated by alkaline comet assay in Swiss albino mice." *Journal of applied genetics* 52.3 (2011): 355-361.
6. Lin, Xinjian, et al. "P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin." *Cancer research* 61.4 (2001): 1508-1516.

7. Miyajima, A., et al. "Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells." *British journal of cancer* 76.2 (1997): 206-210.
8. Laurent, Alexis, et al. "Controlling tumor growth by modulating endogenous production of reactive oxygen species." *Cancer research* 65.3 (2005): 948-956.
9. Godwin, Andrew K., et al. "High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis." *Proceedings of the National Academy of Sciences* 89.7 (1992): 3070-3074.
10. Masuda, Hidetaka, Toshiko Tanaka, and UmeoTakahama. "Cisplatin generates superoxide anion by interaction with DNA in a cell-free system." *Biochemical and biophysical research communications* 203.2 (1994): 1175-1180.
11. Kruidering, Marieke, et al. "Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain." *Journal of Pharmacology and Experimental Therapeutics* 280.2 (1997): 638-649.
12. Di Cesare Mannelli, Lorenzo, et al. "Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin." *The Journal of Pain* 13.3 (2012): 276-284.
13. Di Cesare Mannelli, L., et al. "Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: Could it correlate with in vivo neuropathy ?" *Free Radical Biology and Medicine* 61 (2013): 143-150.
14. Chistyakov, V. A., et al. "Superoxide scavenging activity of plastoquinone derivative 10-(6'-plastoquinonyl) decyltriphenylphosphonium (SkQ1)." *Biochemistry (Moscow)* 77.7 (2012): 776-778.
15. Prazdnova E.V., Chistyakov V.A., M.A. Sazykina and I.S. Sazykin "Study of Prooxidant Action of Ultraviolet Radiation with Wavelength 258 Nm Using Bacterial Biosensors." *Middle-East Journal of Scientific Research* 21.8 (2014): 1333-1340
16. Manukhov, I. V., et al. "Induction of oxidative stress and SOS response in *Escherichia coli* by vegetable extracts: the role of hydroperoxides and the synergistic effect of simultaneous treatment with cisplatin." *Microbiology* 77.5 (2008): 523-529.
17. Giri, Anirudha, Dimos Khyriam, and Surya B. Prasad. "Vitamin C mediated protection on cisplatin induced mutagenicity in mice." *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis* 421.2 (1998): 139-148.
18. Kameyama, Yoshiko, and Munekazu Gemba. "The iron chelatordeferroxamine prevents cisplatin-induced lipid peroxidation in rat kidney cortical slices." *Japanese journal of pharmacology* 57.2 (1991): 259-262.

19. Sha, Su-Hua, et al. "Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals." *Hearing research* 155.1 (2001): 1-8.
20. Ta, Lauren E., et al. "Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA binding." *Neurotoxicology* 27.6 (2006): 992-1002.
21. Orlova, R.V. "New medicaments for colorectal cancer treatment." *Practical oncology (Prakticheskaya onkologiya)* 3.4 (2002): 273.
22. Kopetz, Scott, et al. "Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress." *Cancer research* 69.9 (2009): 3842-3849.